The emergence of a legal recreational cannabis sector has drawn attention away from the medical cannabis market. However, many companies continue to move forward in this strong sector, benefiting from extensive research and development work. PreveCeutical Medical, Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing new cannabis-based medicines and delivery systems through partnership with researchers in Australia. Invictus MD Strategies Corporation (TSX-V: GENE) (OTC: IVITF) has created a network of profitable growing facilities that allowed the company to pay out a million-dollar dividend in 2016, the first dividend payout by a Canadian cannabis company, and Radient Technologies, Inc. (TSX-V: RTI) is partnering with cannabis companies to produce medical cannabis extracts. Already the owner of a large growing facility, WeedMD, Inc. (TSX-V: WMD) is in the process of creating 610,000 square feet of greenhouse space that will increase its cannabis production from 1,500kg to 33,000kg over two phases of expansion. Wildflower Marijuana, Inc. (SUN: CNX) sells a range of cannabis-based products, including vaporizers and soap, and is set to expand in the lucrative California market through new licenses in Los Angeles.
To view the full editorial, visit http://cnw.fm/V2wQj
About PreveCeutical Medical Inc.
PreveCeutical Medical Inc. is a health sciences company that develops innovative preventive therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. For more information visit www.PreveCeutical.com.
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CanadianCannabisWire.com